Biogen stock heads toward October 28 results after 1.69 percent gain

Published on 10/07/2026 at 00:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen's Q2 revenue reached USD 2.736 billion after 3.4 percent year-over-year growth, while GAAP EPS fell to USD 0.66. Jefferies sees Q3 EPS at USD 2.14 versus USD 2.07 consensus.

Draufsicht auf Aktienzertifikat, ISIN-Karte, Gehirnmodell, Molekülmodelle und Stethoskop auf Marmor — Biogen Inc. Flatlay mit Aktienzertifikat ISIN US09062X1037 Gehirnmodell Molekülstruktur DNA-Helix und Forschungsobjekten, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) closed at USD 223.59 on Nasdaq on October 5, 2026, gaining 1.69 percent as the biotechnology company approaches its October 28 results date. Biogen said on September 16, 2026, that it will publish third-quarter financial results before the market opens.

October 28 sets the next test

The upcoming report will test whether Biogen can convert its newer therapies into growth while its multiple sclerosis portfolio faces continuing pressure. Yahoo Finance reported on October 6, 2026, that Jefferies expects adjusted third-quarter EPS of USD 2.14 against consensus of USD 2.07.

The same preview puts quarterly revenue at USD 2.6 billion and says Biogen's 2026 revenue guidance implies growth of 3 percent to 7 percent, or USD 10.19 billion to USD 10.58 billion. Jefferies also expects fourth-quarter Phase III data for litifilimab, an antibody being developed for systemic lupus erythematosus.

Q2 growth came with a profit squeeze

Biogen's second-quarter revenue rose 3.4 percent year over year to USD 2.736 billion for the three months ended June 30, 2026, but GAAP diluted EPS fell to USD 0.66 from USD 4.33. Financial Report Insights attributes the earnings decline to deal and restructuring charges.

The adjusted picture was stronger: adjusted EPS was USD 3.60, down 34 percent from USD 5.47 in the year-earlier quarter. That split matters for the October report because headline revenue growth is currently running ahead of reported earnings growth.

Consensus leaves limited room above price

MarketBeat reported on October 6, 2026, that 33 analysts carried a Moderate Buy consensus, with 18 Buy ratings, 13 Holds, one Strong Buy and one Sell. The average 12-month target was USD 230.14, placing it 2.9 percent above the October 5 price, while published recent targets ranged from USD 215 to USD 300.

Biogen's market capitalization was USD 32.9 billion as of October 6, 2026. Its Nasdaq 52-week range was USD 138.00 to USD 230.49, leaving the October 5 close within 3.0 percent of the upper end.

Biogen stock stays near its yearly high

Biogen stock closed at USD 223.59 on October 5, 2026, with the session's gain keeping the price near its USD 230.49 52-week high. The October 28 revenue, EPS and litifilimab updates now provide the next dated checkpoints for the shares.